在RAS突变瘤中准RAF二元体:从生物学到临床
Huanhuan Yin1, Qiulin Tang1, Hongwei Xia1
1Division of Abdominal Cancer, Department of Medical Oncology, Cancer Center and Laboratory of Molecular Targeted Therapy in Oncology, West China Hospital, Sichuan University, Chengdu 610041, China.
Acta pharmaceutica Sinica. B
|May 27, 2024
概括
准RAF二分化为治疗RAS突变癌症提供了新的希望,克服了当前治疗方法的局限性. 单独使用II型RAF抑制剂或与MEK/ERK抑制剂结合使用,对这些难以治疗的瘤具有有前途的作用.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药物发现 药物发现 药物发现
背景情况:
- 在约30%的癌症中,RAS突变很普遍,与预后不佳和治疗选择有限有关.
- 向KRAS G12C突变显示成功,但其他RAS突变的有效治疗仍然难以捉摸.
- 在RAS下游的MAPK通路是关键的治疗点,特别是RAF激酶.
研究的目的:
- 审查RAF二分化在RAS突变瘤和治疗耐药性的重要性.
- 探索针对RAF二分化在RAS突变癌症中的近期治疗策略.
主要方法:
- 对RAS突变,MAPK通路信号和RAF抑制剂开发的现有文献的审查.
- 对评估II型RAF抑制剂和组合疗法的临床研究进行分析.
主要成果:
- 第一代RAF抑制剂在RAS突变瘤中是无效的,原因是RAF二分化引起的矛盾ERK激活.
- II型RAF抑制剂通过解决RAF二分化,在RAS突变的瘤中显示初始疗效.
- 与II型RAF抑制剂和MEK/ERK抑制剂的联合治疗显示出显著的疗效.
结论:
- RAF二分化是推动RAS突变癌症抗性的关键机制.
- 二型RAF抑制剂代表了RAS突变瘤的一个有前途的治疗途径.
- 针对RAF二分化和下游效应因子的组合策略提供强大的抗癌活性.
相关概念视频
Small GTPases - Ras and Rho
3.9K
Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
Three regulatory proteins control their activity:
3.9K
The Ras Gene
6.2K
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
Ras is a...
6.2K
Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
MAPK Signaling Cascades
5.4K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
5.4K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K


